UCB reports FDA approval for Zilbrysq device: UCB stock gains 2.05 percent

Published on 10/20/2026 at 10:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Deutsche Bank keeps a EUR 295.00 target on October 16, 2026. UCB stock costs EUR 209.40 on October 20, 2026, 2.05 percent above the Xetra close.

Clinical access and growth markers

UCB received FDA approval for a Zilbrysq device on October 16, 2026, based partly on a 31-patient study.
UCB reported EUR 4.27 billion in revenue for the first half of 2026, up 23.00 percent year over year.
UCB stock trades at EUR 209.40 at 10:36 a.m. CEST at Lang & Schwarz on October 20, 2026, 2.05 percent above the Xetra close of October 19, 2026.

Isometrische 3D-Illustration einer Wertschöpfungskette von Labor über Produktion bis zum Krankenhaus — UCB S.A. mit ISIN BE0003739530 dargestellt als isometrisches 3D-Diagramm der biopharmazeutischen Wertschöpfungskette, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) was trading at EUR 209.40 at Lang & Schwarz on October 20, 2026 at 10:36 a.m. CEST, up 2.05 percent versus the Xetra close of October 19, 2026 at EUR 205.20. The latest company catalyst was a US FDA approval for a new Zilbrysq administration option, as MarketScreener reported on October 16, 2026.

FDA access adds a practical option

The approval covers a daily auto-injector for adults with generalized myasthenia gravis and adds a self-administration route to the existing prefilled syringe. The phase 3b study included 31 patients, while 99.80 percent of auto-injector administrations delivered a full dose, according to MarketScreener. UCB expects to commercialize the device in the first quarter of 2027.

Three milestones shape the story

UCB's recent chronology includes one FDA breakthrough therapy designation for CIMZIA on September 9, 2026, first-half 2026 revenue of EUR 4.27 billion, and the October 16, 2026 Zilbrysq approval. The company investor page reports that first-half revenue rose 23.00 percent year over year and that BIMZELX sales reached EUR 1.52 billion in the same period, with more than 135,000 patients reached globally, according to UCB.

What supports the valuation?

Deutsche Bank kept a buy rating and a EUR 295.00 target on October 16, 2026, according to MarketScreener. The target is 40.84 percent above the Lang & Schwarz price, while the stock remains inside its EUR 197.45 to EUR 289.50 52-week range as of October 20, 2026.

Upcoming dates for UCB

UCB's next dated reporting event is the annual 2026 earnings release on February 24, 2027. The investor page also lists first-quarter 2027 commercialization for the Zilbrysq auto-injector, while the pipeline includes further clinical readouts in the second half of 2027, according to UCB.

Stock trades above the Xetra close

UCB has a market capitalization of EUR 39.9 billion as of October 20, 2026. Its current Lang & Schwarz price of EUR 209.40 was 2.05 percent above the Xetra close of EUR 205.20 dated October 19, 2026.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.